Table 2 Comparison of Takayasu arteritis (TAK) patients with and without relapse during the follow-up.
From: Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
All TAK patients (n = 52) | Patients with relapses (n = 27) | Patients without relapses (n = 25) | |
|---|---|---|---|
Characteristics at diagnosis | |||
Age (years) (medians; ranges) | 37.5 [16–63] | 42 [18–53] | 35 [16–50] |
Females (n; %) | 43 (83%) | 21 (77%) | 22 (88%) |
Vascular signs | 41 (79) | 20 (74) | 21 (84) |
Fever / Weight loss (n; %) | 30 (58) | 15 (55) | 15 (60) |
C-reactive protein (mg/L) (medians; ranges) | 43 [0–230] | 50 [1–230] | 20 [1–144] |
NIH disease activity score at diagnosis (medians, ranges) | 3 [1–4] | 3 [1–4] | 3 [1–4] |
Cardiovascular risk factors at diagnosis | |||
Diabetes mellitus (n; %) | 1 (2) | 0 | 1 (4) |
Hypertension (n; %) | 19 (37) | 10 (37) | 9 (38) |
Smokers (n; %) | 16 (31) | 3 (11) | 13 (52)* |
Hyperlipidemia (n; %) | 8 (15) | 5 (19) | 3 (12) |
Body mass index | 25.8 [17.6–38] | 25.8 [19–32] | 25.8 [17.6–38] |
TAK treatments | |||
Glucocorticoids at diagnosis | 40 (82) | 24 (88) | 16 (64)* |
Glucocorticoids at any time | 44 (85) | 26 (96) | 18 (72)* |
Additional immunosuppressants (n, %) at any time | 28 (62) | 21 (78) | 7 (28)* |
Biological-targeted therapies at any time (n, %) | 35 (67) | 24 (89) | 11 (44)* |
Cardiovascular risk factors therapies | |||
Aspirin (n; %) | 36 (69) | 19 (70) | 17 (68) |
Anticoagulants | 5 (9.6) | 3 (11) | 2 (8) |
Statins (n; %) | 16 (32) | 8 (32) | 8 (32) |
Antihypertensive drugs (n, %) | 25 (50) | 16 (59) | 9 (36) |
ACE inhibitor (n, %) | 15 (29) | 10 (37) | 5 (20) |
Betablockers (n, %) | 17 (33) | 12 (44) | 5 (20) |
Follow-up (years) | 4.2 | 4.3 | 4.0 |
